Gilead Stock News

It is currently benefiting from a pandemic tailwind, but for how much longer?

Friday afternoon''s top analyst upgrades and downgrades included Apple, Gilead, Goldman Sachs, Kroger, Raymond James, and more.

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) fourth-quarter 2021 results.

Five corporate behemoths will report fourth-quarter 2021 earnings results next week. These are: TMO, FB, GOOGL, GILD and UPS.

Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.

LABU - A Compelling Biotech Trade

The FDA has placed a partial clinical hold on Gilead Sciences Inc''s (NASDAQ: GILD ) studies evaluating the combination of magrolimab plus azacitidine. Due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions (SUSARs) between study arms, the agency has taken action. While no clear trend in the adverse reactions or new safety signal has Full story available on Benzinga.com

"Indefensible Edict" - DeSantis Rages After Biden''s FDA Restricts Use Of Monoclonal Antibody Treatments Governor Ron DeSantis is demanding the Biden Administration reverse its sudden decision to revoke emergency use authorization (EUA) for monoclonal antibody treatments. In a statement from the Florida Governor''s office , he rages that this abrupt and unilateral action by the Biden Administration will prevent access to lifesaving treatments for Floridians and Americans. Without a shred of clinical data to support this action, Biden has forced trained medical professionals to choose between treating their patients or breaking the law, said Governor Ron DeSantis. This indefensible edict takes treatment out of the hands of medical professionals and will cost some Americans their lives. There are real-world implications to Bidens medical authoritarianism Americans access to treatments is now subject to the whims of a failing president. Rather than giving Americans the option for various COVID treatments, the FDA and the Biden Administration issued their royal decree, taking away the very thing that is proven to reduce hospitalizations and save lives, said Lieutenant Governor Jeanette Nuñez. Monoclonal antibody treatments like Regeneron have had a positive impact for thousands of Floridians.

Pharma giants like Pfizer (PFE), Merck (MRK) and Eli Lilly (LLY), along with biotech bigwig Regeneron (REGN), are down on regulatory updates.

Gilead Sciences (GILD) closed the most recent trading day at $68.57, moving +0.09% from the previous trading session.

Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.

Gilead''s COVID-19 treatment Veklury (remdesivir) can now be used in non-hospitalized adults and adolescents at high risk of progressing to severe disease.

The biopharmaceutical company Gilead Sciences announced Wednesday a massive web of seizures across several states of "counterfeit and tampered Gilead HIV medication within the U.S. supply chain."

Gilead Sciences Inc (NASDAQ: GILD ) said an unauthorized network of drug distributors and suppliers sold pharmacies more than $250 million of counterfeit versions of its HIV treatments over the last two years. The alleged scheme was reported earlier by The Wall Street Journal . The Company found 85,247 bottles tampered with or faked, including versions of its Biktarvy and Descovy treatments. Gilead said it had seized Full story available on Benzinga.com